ZymoGenetics Closes $90M Deal

ZymoGenetics, the Seattle-based biotech company, said today its underwriters have exercised their options to buy all the shares they were granted, bringing its net proceeds from the latest offering to $90.9 million. Investors and underwriters bought a total of 16.1 million shares at $6 apiece, ZymoGenetics said. The money will be used to support R&D, and to help market the company's lone approved drug, recombinant thrombin (Recothrom).